

**MARISA TUNGSIRIPAT, MD**Department of Infectious Diseases,  
The Cleveland Clinic Foundation**JUDITH A. ABERG, MD\***Associate Professor of Medicine, Director of  
HIV, Bellevue Hospital Center, Director of AIDS  
Clinical Trials Unit, New York University

# Dyslipidemia in HIV patients

## ■ ABSTRACT

Thanks to antiretroviral therapy, people with human immunodeficiency virus (HIV) infection are living longer, but as they do, non-HIV medical problems become more relevant. In particular, dyslipidemia, an important reversible risk factor for cardiovascular disease, has been linked to HIV infection and its treatment. Although controversy remains as to whether people with HIV infections will develop premature coronary heart disease, it seems prudent to manage dyslipidemia in these patients just as we do in our HIV-negative patients. Interactions between lipid-lowering drugs and antiretroviral drugs require special attention.

## ■ KEY POINTS

Symptoms that suggest cardiovascular events that we might initially dismiss as noncardiac in younger patients without traditional cardiac risk factors may in fact be significant in HIV-infected patients with dyslipidemia.

The severity of the dyslipidemia and the typical pattern of the lipid profile differ among and within the classes of antiretroviral agents. Also, dyslipidemia does not develop in everyone who takes these drugs, suggesting that host factors play a major role in its development.

Lipid effects are only one factor to consider when choosing antiretroviral drugs, and because dyslipidemia in HIV patients is often multifactorial, switching antiretroviral drugs may not resolve the dyslipidemia.

Giving statins to patients receiving antiretroviral therapy can cause problems, since many statins and some antiretroviral drugs are metabolized by the same cytochrome P450 isoenzyme, CYP3A4, and inhibition of the isoenzymes may result in excessively high levels of statins.

**H**UMAN IMMUNODEFICIENCY VIRUS (HIV) seems to raise people's lipid levels, as do the antiretroviral drugs used to treat it.

Although we do not yet know that people with HIV will develop premature coronary heart disease, we have no reason to expect that they would be immune to the cardiovascular effects of dyslipidemia, especially given their longer life-span due to the effectiveness of antiretroviral therapy. Therefore, it is prudent to treat their dyslipidemia as aggressively as we do in those without HIV, with the added caveat that many lipid-lowering drugs have interactions with antiretroviral drugs.

In this article we examine the data linking HIV and antiretroviral therapy with dyslipidemia and discuss the role of lipid-lowering drugs in HIV patients.

## ■ SURVIVAL IS INCREASING

Antiretroviral therapy has reduced the rates of sickness and death and has increased survival in patients with HIV infection,<sup>1</sup> at least in countries where people have access to it. For example, the adjusted death rate from HIV and acquired immunodeficiency syndrome (AIDS) in the United States declined nearly 4% from 2000 to 2001,<sup>2</sup> a larger decline than in the previous year, and continuing a trend that began in 1995. Indeed, HIV-related deaths decreased by nearly 70% over this 6-year period.<sup>2,3</sup>

As people with HIV infection live longer, non-HIV medical conditions become more important and relevant, particularly coronary heart disease, the leading cause of death in the United States.<sup>4</sup>

\*The author has indicated that she is a consultant for Bristol-Myers Squibb, Boehringer-Ingelheim, Gilead Sciences, and Glaxo-SmithKline. She received research support from Bristol-Myers Squibb, Abbott, and Merck and is active in the leadership for the National Institute of Allergy and Infectious Diseases-sponsored AIDS Clinical Trials Group.

TABLE 1

**Current antiretroviral drugs****Nucleoside/nucleotide reverse transcriptase inhibitors**

Abacavir  
Didanosine  
Emtricitabine  
Lamivudine  
Stavudine  
Tenofovir  
Zalcitabine  
Zidovudine

**Non-nucleoside reverse transcriptase inhibitors**

Delavirdine  
Efavirenz  
Nevirapine

**Protease inhibitors**

Amprenavir/fosamprenavir  
Atazanavir  
Indinavir  
Lopinavir/ritonavir  
Nelfinavir  
Ritonavir  
Saquinavir  
Tipranavir

**Fusion inhibitor**

Enfuvirtide

**HIV itself  
has been  
associated  
with  
dyslipidemia**

The risk factors for cardiovascular disease have cumulative and interacting effects. While some risk factors such as male sex and family history are not modifiable, others are, including unhealthy diet, smoking, hypertension, dyslipidemia, diabetes, and physical inactivity. Aggressive treatment of dyslipidemia is key to managing and preventing cardiovascular disease in patients with or without HIV infection.

**■ ANTIRETROVIRAL DRUGS AND REGIMENS**

Current antiretroviral drugs comprise four classes (TABLE 1):

- Nucleoside/nucleotide reverse transcriptase inhibitors: zidovudine, lamivudine, emtricitabine, stavudine, didanosine, zalcitabine, abacavir, tenofovir
- Non-nucleoside reverse transcriptase inhibitors: efavirenz, nevirapine, delavirdine

- Protease inhibitors: amprenavir/fosamprenavir, atazanavir, indinavir, lopinavir/ritonavir, nelfinavir, saquinavir, tipranavir, ritonavir (not commonly used as the sole protease inhibitor in an antiretroviral regimen, but often used in low doses to “boost” the levels of other protease inhibitors).

- Fusion inhibitors, of which only enfuvirtide is approved by the US Food and Drug Administration (FDA).

**Highly active antiretroviral therapy**

“Highly active” antiretroviral therapy (HAART) is a term used to distinguish aggressive multidrug regimens from earlier, less potent ones. Currently, antiretroviral therapy (ART) and HAART both refer to any potent combination of agents that can reduce the plasma HIV level to less than can be detected by polymerase chain reaction or b-DNA assay. These regimens most often consist of a protease inhibitor or non-nucleoside reverse transcriptase inhibitor in addition to a “backbone” of two nucleoside reverse transcriptase inhibitors.

**■ LIPID EFFECTS OF HIV AND ANTIRETROVIRAL DRUGS**

HIV has been associated with dyslipidemia independent of antiretroviral therapy.<sup>5</sup> Grunfeld et al<sup>6</sup> found that HIV infection was associated with elevated triglyceride levels that worsened with progression of HIV-related disease.

Antiretroviral therapy can also contribute to dyslipidemia. Dyslipidemia has been described as being more common and more severe in HIV patients receiving antiretroviral therapy than in patients not on therapy.<sup>7–9</sup>

The severity of the dyslipidemia and the typical pattern of the lipid profile differ among and within the classes of antiretroviral agents.<sup>10</sup> Also, dyslipidemia does not develop in everyone who takes these medications, suggesting that host factors play a major role in its development.

**Reverse transcriptase inhibitors**

Non-nucleoside reverse transcriptase inhibitors have been associated with elevated levels of high-density lipoprotein cholesterol (HDL-C)

and total cholesterol.<sup>11</sup>

Nucleoside reverse transcriptase inhibitors, on the other hand, are heterogeneous in their lipid effects, which may depend somewhat on interactions with other antiretroviral drugs in the regimen.<sup>12,13</sup> For example, stavudine is often associated with elevated total cholesterol, low-density lipoprotein cholesterol (LDL-C), and triglyceride levels.

In comparison, tenofovir appears to be more “lipid-friendly” than other nucleoside reverse transcriptase inhibitors.<sup>12,14</sup> Cheng et al<sup>14,15</sup> found that, after 24 weeks of therapy, total cholesterol levels decreased by 17.5 mg/dL in patients receiving tenofovir, compared with a decrease of 3.8 mg/dL in patients receiving placebo. Triglyceride levels decreased by 24 mg/dL in the tenofovir group and by 3.4 mg/dL in the placebo group. When the placebo group crossed over to receive tenofovir from weeks 24 to 48, their total cholesterol levels decreased by 12.1 mg/dL and triglyceride levels by 22.0 mg/dL.

### Protease inhibitors

Protease inhibitors are generally associated with elevated levels of total cholesterol and triglycerides. Triglyceride levels of greater than 1,000 mg/dL have been reported in association with protease inhibitors.<sup>7</sup> Carr et al<sup>8</sup> reported elevated total cholesterol levels, defined as greater than 5.5 mmol/L, in 58% of patients receiving protease inhibitors vs 11% of those not receiving them; elevated triglycerides, defined as greater than 2.0 mmol/L, were seen in 50% of patients receiving these drugs vs 22% of those not receiving them. Segerer et al,<sup>9</sup> in another study, reported a 15% increase in total cholesterol and a 25% increase in triglycerides after 3 to 6 months of protease inhibitor therapy.

All protease inhibitors are not the same in regard to dyslipidemia, however, and lipid abnormalities may vary. Ritonavir has been most associated with triglyceride elevations, whereas indinavir is more associated with elevations of LDL-C. Atazanavir is an exception in that it appears to have very little or no effect on cholesterol and triglycerides. In a trial comparing atazanavir with nelfinavir, both with a backbone of stavudine and lamivudine, nelfinavir was associated with an

approximately 50% increase in triglyceride levels vs a 7% increase with atazanavir.<sup>16</sup>

### Sex and ethnicity may influence lipid effects

Kumar et al,<sup>13</sup> in a trial comparing three antiretroviral regimens (zidovudine-lamivudine-abacavir, zidovudine-lamivudine-nelfinavir, and stavudine-lamivudine-nelfinavir), found that among patients taking nelfinavir, women were more likely than men to develop increased LDL-C, and the association between female sex and LDL-C elevations was even stronger in those taking stavudine-lamivudine-nelfinavir than with the two other regimens. Also, black patients were more likely than white or Hispanic patients to develop increased LDL-C levels, whereas Hispanic patients had more significant elevations of triglycerides.<sup>17</sup>

Unfortunately, this study was underpowered to evaluate these apparent effects more specifically. Also, the people studied may not be representative of all members classified within a group.

### HIV, antiretroviral therapy, and the metabolic syndrome

Exactly how HIV and antiretroviral therapy cause dyslipidemia has not been determined. The dyslipidemia can occur with or without the metabolic syndrome (insulin resistance, central fat accumulation, peripheral fat loss, and inflammatory states), which in the general population is associated with an increased risk of cardiovascular events and which the National Cholesterol Education Program (NCEP) has identified as a secondary target for prevention of cardiovascular events.<sup>18</sup> In patients with HIV, the metabolic syndrome has many of the same features as in HIV-negative patients.

### ■ DOES HIV THERAPY INCREASE CARDIAC RISK?

Although HIV and its treatment have been associated with dyslipidemia in some studies, no one has definitively established that this association translates to an increased risk of cardiovascular events. The relatively long natural history of cardiovascular disease and

**The metabolic syndrome in HIV resembles that in non-HIV patients**

risk interventions makes it difficult to establish this relationship.

For example, investigators for the Kaiser Permanente HIV Cohort<sup>19</sup> reported that in a study of more than 5,000 HIV-infected patients, both cardiovascular disease and myocardial infarction rates were significantly higher among the HIV-infected patients. During the 3-year study period from 2001 to 2004, 22% of patients started lipid-lowering therapy, and 27% started a regimen containing atazanavir. Stavudine use had declined from 48% to 17%.

There is no evidence to suggest that HIV patients would be not be vulnerable to the increased cardiovascular risk associated with dyslipidemia in HIV-negative patients.

### Risk of myocardial infarction

The most compelling evidence that dyslipidemia in HIV patients may increase the risk of myocardial infarction comes from the Data Collection of Adverse Events of Anti-HIV Drugs study.<sup>20</sup> In this prospective, observational study, the relative risk of myocardial infarction attributed to antiretroviral therapy increased by 26% per year. Despite such limitations as short follow-up, this finding suggests that we should not disregard dyslipidemia in HIV patients.

Consequently, patients with HIV, especially those receiving antiretroviral therapy, should be regularly screened for dyslipidemia. Furthermore, in patients with preexisting cardiovascular risk factors, the most lipid-friendly antiretroviral drugs should be chosen as initial therapy. Obviously, HIV itself should be treated first with considerations for underlying comorbidities.

Moreover, we need to take seriously any symptoms that suggest cardiovascular events in HIV-infected patients with dyslipidemia, even though we might consider the same symptoms noncardiac in younger patients without traditional cardiac risk factors or HIV.

## TREATMENT

### Targeting LDL cholesterol

Recommendations for managing dyslipidemia in HIV patients are based on the NCEP's third Adult Treatment Panel guidelines for the general population.<sup>21</sup>

The first step is to assess the patient's cardiovascular risk, which affects the decision whether to start treatment and the goals of treatment. The main factor is the LDL-C concentration, but the assessment also takes into account other risk factors such as confirmed cardiovascular disease, age older than 45 years in men and 55 in women, cigarette smoking, hypertension, low HDL-C (< 40 mg/dL), and diabetes.<sup>18</sup>

The level of cardiovascular risk is traditionally classified as low, intermediate, or high, and each category entails a different LDL-C treatment goal:

- Lowest risk means no risk factors or one risk factor; the goal LDL-C concentration is less than 160 mg/dL.
- Intermediate risk means one or two risk factors; the goal LDL-C is less than 130 mg/dL.
- High risk means confirmed coronary heart disease or coronary heart disease equivalents, or two or more cardiovascular risk factors and a Framingham 10-year risk score of 20%; the goal LDL-C is less than 100 mg/dL.<sup>18</sup>

In view of several recent studies,<sup>22–26</sup> the NCEP recently modified these guidelines to include an LDL-C goal of less than 70 mg/dL as an option in patients at very high risk, ie, those with established cardiovascular disease and multiple major risk factors (especially diabetes), severe and poorly controlled risk factors, multiple risk factors of the metabolic syndrome, and acute coronary syndromes.<sup>27</sup>

### Targeting triglycerides, other lipids

Although lower LDL-C levels are the primary goal of lipid-lowering therapy, the triglyceride level and the “non-HDL” cholesterol level (ie, total cholesterol minus HDL-C) are often significant factors in patients with antiretroviral therapy-related dyslipidemia, who commonly have triglyceride elevations.

When triglyceride levels are borderline-high (150–199 mg/dL), dietary and exercise interventions are emphasized. When triglyceride levels are high (200–499 mg/dL), non-HDL cholesterol becomes a secondary target of therapy. When triglyceride levels are 500 mg/dL or higher, triglycerides are the primary target of therapy. The NCEP guidelines recommend non-HDL cholesterol as a secondary

**Tenofovir appears to be more 'lipid-friendly' than other nucleoside reverse transcriptase inhibitors**



TABLE 2

**Drug interactions of antiretroviral drugs and lipid-lowering drugs**

	PROTEASE INHIBITORS		NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS	
	REGULAR DOSE	'BOOSTER' DOSE	EFAVIRENZ	NEVIRAPINE
<b>Statins</b>				
Simvastatin	Increase "area under the curve" (AUC) of simvastatin by 505% to 3,059% Do not coadminister <sup>29,38,39</sup>	May increase blood levels of simvastatin Do not coadminister <sup>40</sup>	Decreases AUC of simvastatin by 58% May need to increase simvastatin dose <sup>32</sup>	No data
Atorvastatin	Increase AUC of atorvastatin by 71%–130% Use lowest starting dose of atorvastatin <sup>38,39,41</sup>	Increase AUC of atorvastatin by 130%–488% Use lowest starting dose of atorvastatin <sup>41,42</sup>	Decreases AUC of atorvastatin by 43% Higher dose of atorvastatin may be needed <sup>32</sup>	No data
Pravastatin	Minimal change in pravastatin level No dose adjustment <sup>29,32</sup>	Minimal change in pravastatin level No dose adjustment <sup>40,44</sup>	No data	No data
<b>Fibrates<sup>21</sup></b>	Possible reduced effect No dose adjustment	Possible reduced effect No dose adjustment	Probably no change No dose adjustment	Probably no change No dose adjustment
<b>Niacin<sup>21</sup></b>	Probably no change No dose adjustment	Probably no change No dose adjustment	Probably no change No dose adjustment	Probably no change No dose adjustment
<b>Bile acid sequestrants<sup>21</sup></b>	May interfere with antiretroviral therapy absorption Do not coadminister	May interfere with antiretroviral therapy absorption Do not coadminister	May interfere with antiretroviral therapy absorption Do not coadminister	May interfere with antiretroviral therapy absorption Do not coadminister

target of therapy in people with high triglyceride levels (200 mg/dL). The goals for non-HDL cholesterol are defined as 30 mg/dL higher than those for LDL-C.<sup>18</sup>

### Starting treatment

Starting treatment of dyslipidemia in HIV patients is similar to starting it in any other patients. Some situations call for drug therapy to be started in combination with lifestyle changes. However, a trial of nondrug interventions such as diet and exercise is generally recommended first. Other reversible risk factors such as smoking, diabetes, and hypertension should also be addressed at this time.<sup>16</sup>

### Adapting the antiretroviral regimen

Because antiretroviral therapy has been implicated as a cause of dyslipidemia, altering the antiretroviral regimen has been evaluated as a

way to minimize or reverse this dyslipidemia. However, lipid effects are only one factor to consider when choosing antiretroviral drugs, and because dyslipidemia in HIV patients is often multifactorial, switching antiretroviral drugs may not resolve the dyslipidemia. Therefore, switching antiretroviral drugs should be considered but may not always be a viable option.

### Lipid-lowering drugs

The lipid-lowering agents commonly used to treat lipid disorders in the general population are HMG-CoA reductase inhibitors (statins), fibric acid derivatives (fibrates), bile acid binding resins, niacin, and inhibitors of intestinal absorption such as ezetimibe. Of these, statins are the first-line treatment if the primary problem is elevated LDL-C or non-HDL cholesterol levels and with triglyceride



levels below 500 mg/dL, as they have been shown to reduce the progression of coronary artery stenosis and to reduce the risk of subsequent myocardial events.<sup>28</sup>

Statins should also be the first-line treatment in HIV patients with increased LDL-C or non-HDL cholesterol levels and with triglyceride levels below 500 mg/dL. The HIV Medical Association of the Infectious Disease Society of America and the AIDS Clinical Trials Group advocate using statins for initial therapy if the primary problem is elevated LDL-C and non-HDL cholesterol. When the primary risk factor is elevated triglycerides, they recommend starting with a fibrate.<sup>21</sup>

TABLE 2 lists interactions between antiretrovirals and lipid-lowering drugs.

### Statin drug interactions with antiretroviral therapy

Giving statins to patients receiving antiretroviral therapy can cause problems, since many statins and some antiretroviral drugs are metabolized by the same cytochrome P450 isoenzyme CYP3A4, and inhibition of the isoenzymes may result in excessively high levels of statins.

**Simvastatin and protease inhibitors.** A 30-fold increase in the area under the curve of simvastatin has been seen when it is given with ritonavir-boosted saquinavir,<sup>29</sup> greatly increasing the risk of rhabdomyolysis.<sup>30</sup> These findings suggest that simvastatin should be avoided in patients taking protease inhibitors.

**Lovastatin** would be expected to behave in the same way.

**Atorvastatin** levels may also increase when it is given with protease inhibitors; however, as these increases are not to the point of toxicity, atorvastatin can be used, but at lower doses than in the general population.<sup>21</sup>

**Pravastatin** metabolism is complex, utilizing both oxidative and conjugative enzymes for elimination, but CYP3A4 is not a significant enzyme in its metabolism. Therefore, it appears a safe option in patients taking protease inhibitors. However, pravastatin may be less effective at lowering lipid levels in these patients due to the induction of enzymes responsible for the metabolism of pravastatin.

**Rosuvastatin.** The guidelines of the HIV Medical Association of the Infectious Disease Society of America and the AIDS Clinical

Trials Group do not mention rosuvastatin, which was not yet approved at the time the guidelines were published. Rosuvastatin has the potential to be an effective option in dyslipidemia related to antiretroviral therapy because of its potency. Rosuvastatin is metabolized similarly to pravastatin but may have slightly more CYP3A4 activity.<sup>31</sup> However, in the absence of data, no formal recommendations can be made.

**Statins and non-nucleoside reverse transcriptase inhibitors.** Efavirenz has been shown to decrease the area under the curve of atorvastatin by 43%<sup>32</sup> and of simvastatin by 58%, suggesting that higher doses of atorvastatin and simvastatin may be needed to effectively reduce LDL-C in patients taking efavirenz.

Statins do not appear to have any effect on HIV drugs.

### Other lipid-lowering drugs

**Fibrates** have been described as safe for people with HIV.<sup>33</sup> However, their main use would be in patients with hypertriglyceridemia. Another advantage of fibrates is that they increase HDL-C.

**Niacin** is another option for patients with high triglycerides. A small pilot study suggested that it may be safe in HIV patients on antiretroviral therapy.<sup>34</sup> However, the HIV Medical Association of the Infectious Disease Society of America and the AIDS Clinical Trials Group guidelines do not advocate using it as first-line therapy in patients receiving protease inhibitors or with lipodystrophy because of the potential for insulin resistance. Additional studies evaluating the safety of niacin among HIV patients are ongoing.

**Fish oil.** A pilot study evaluated the efficacy of fish oil for hypertriglyceridemia. After 8 weeks of therapy, patients randomized to receive 2 g of fish oil had a 26% reduction in triglyceride levels compared with a 1% increase in the placebo group ( $P = .003$ ).<sup>35,36</sup>

**Bile sequestrants** are not recommended because they can interfere with the absorption of antiretroviral drugs.

**Other treatments** need to be tested, since lipid-lowering goals are not always achieved with current treatments. A trial comparing fenofibrate and pravastatin for the treatment of antiretroviral-therapy-related elevations of LDL-C and triglycerides showed that only 3%

Statins are the first-line treatment in HIV patients with high LDL-C or non-HDL cholesterol

of patients achieved their NCEP lipid-lowering goals with a single agent, as did only 16% of patients who received fenofibrate and then added pravastatin.<sup>37</sup> This study showed that patients on combination fenofibrate and

pravastatin therapy received substantial lipid-lowering benefits similar to those in the general population, but this combination is unlikely to achieve all clinical goals recommended by the NCEP.

## REFERENCES

1. Palella FJ Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. *N Engl J Med* 1998; 338:853–860.
2. US Centers for Disease Control and Prevention. Deaths: preliminary data for 2001. Available at: [www.cdc.gov/nchs/data/nvsr/nvsr51/nvsr51\\_05.pdf](http://www.cdc.gov/nchs/data/nvsr/nvsr51/nvsr51_05.pdf). Last accessed September 19, 2005.
3. US Centers for Disease Control and Prevention. Deaths: final data for 1987–1999 and preliminary data for 2000. Available at [www.cdc.gov/nchs/deaths.htm](http://www.cdc.gov/nchs/deaths.htm). Last accessed September 26, 2005.
4. US Centers for Disease Control and Prevention. Preventing Heart Disease and Stroke. Available at [www.cdc.gov/nccdphp/bb\\_heartdisease/index.htm](http://www.cdc.gov/nccdphp/bb_heartdisease/index.htm). Last accessed September 19, 2005.
5. Riddler SA, Smit E, Cole SR, et al. Impact of HIV infection and HAART on serum lipids in men. *JAMA* 2003; 289:2978–2982.
6. Grunfeld C, Kotler DP, Shigenaga JK, et al. Circulating interferon-alpha levels and hypertriglyceridemia in the acquired immunodeficiency syndrome. *Am J Med* 1991; 90:154–162.
7. Sullivan AK, Nelson MR. Marked hyperlipidaemia on ritonavir therapy. *AIDS* 1997; 11:938–939.
8. Carr A, Samaras K, Thorisdottir A, Kaufmann GR, Chisholm DJ, Cooper DA. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. *Lancet* 1999; 353:2093–2099.
9. Segerer S, Bogner JR, Walli R, Loch O, Goebel FD. Hyperlipidemia under treatment with protease inhibitors. *Infection* 1999; 27:77–81.
10. Fontas E, van Leth F, Sabin CA, et al. Lipid profiles in HIV-infected patients receiving combination antiretroviral therapy: are different antiretroviral drugs associated with different lipid profiles? *J Infect Dis* 2004; 189:1056–1074.
11. van Leth F, Phanuphak P, Stroes E, et al. Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naïve patients infected with HIV-1. *PLoS Med* 2004; 1:e19.
12. Gallant JE, Staszewski S, Pozniak AL, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients: a 3-year randomized trial. *JAMA* 2004; 292:191–201.
13. Kumar P, Rodriguez-French A, Thompson M. Prospective Study of Hyperlipidemia in ART-naïve Subjects taking Combivir/Abacavir (COM/ABC), COM/ Nelfinavir (NFV), or Stavudine (d4t)/Lamivudine (3TC)/ NFV (ESS40002) [abstract no. 33]. 9th Conference on Retroviruses and Opportunistic Infections. Seattle, WA, February 24–28, 2002.
14. Cheng A, et al. 2-year long-term safety profile of tenofovir DF (TDF) in treatment-experienced patients from randomized, double-blind, placebo-controlled clinicals [abstract 7.3/7]. 9th European AIDS Conference (9th EACS), Warsaw, Poland, October 25–29, 2003.
15. Gilead Sciences, personal communication.
16. Murphy RL, Sanne I, Cahn P, et al. Dose-ranging, randomized, clinical trial of atazanavir with lamivudine and stavudine in antiretroviral-naïve subjects: 48-week results. *AIDS* 2003; 17:2603–2614.
17. Kumar P, Willimas V, Tashima K, et al. Determinants of hyperlipidemia in ARV-naïve subjects treated with trizivir (TZV), combivir (COM)/nelfinavir (NFV), or stavudine (d4t)/lamivudine (3TC)/NFV [abstract 713]. 11th Conference on Retroviruses and Opportunistic Infections. San Francisco, CA, February 8–11, 2004.
18. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). *JAMA* 2001; 285:2486–2497.
19. Klein D, Hurley L, Quesenberry C. Hospitalizations for CHD and MI among Northern California HIV+ and HIV- Med: additional follow-up and changes in practice. 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 22–25, 2005.
20. Friis-Møller N, Sabin CA, Weber R, et al. Combination antiretroviral therapy and the risk of myocardial infarction. *N Engl J Med* 2003; 349:1993–2003.
21. Dube MP, Stein JH, Aberg JA, et al. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. *Clin Infect Dis* 2003; 37:613–627.
22. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. *Lancet* 2002; 360:7–22.
23. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. *Lancet* 2002; 360:1623–1630.
24. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). *JAMA* 2002; 288:2998–3007.
25. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. *Lancet* 2003; 361:1149–1158.
26. Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. *N Engl J Med* 2004; 350:1495–1504.
27. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. *Circulation* 2004; 110:227–239.
28. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit: impact of statin trials. *Circulation* 1998; 97:946–952.
29. Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interactions between protease inhibitors and statins in HIV seronegative volunteers: ACTG Study A5047. *AIDS* 2002; 16:569–577.
30. Aboulafia DM, Johnston R. Simvastatin-induced rhabdomyolysis in an HIV-infected patient with coronary artery disease. *AIDS Patient Care STDS* 2000; 14:13–18.
31. Shepherd J, Hunninghake DB, Stein EA, et al. Safety of rosuvastatin. *Am J Cardiol* 2004; 94:882–888.
32. Gerber JG, Rosenkranz SL, Fichtenbaum CJ, et al. The effect of efavirenz on the pharmacokinetics of simvastatin, atorvastatin, and pravastatin: results of ACTG 5108 study. *J Acquir Immune Defic Syndr* 2005; 39:307–312.
33. Miller J, Brown D, Amin J, et al. A randomized, double-blind study of gemfibrozil for the treatment of protease inhibitor-associated hypertriglyceridaemia. *AIDS* 2002; 16:2195–2200.
34. Gerber MT, Mondy KE, Yarasheski KE, et al. Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy. *Clin Infect Dis* 2004; 39:419–425.
35. De Truchis P, Kirstetter M, Perier A. Treatment of hypertriglyceridemia in HIV-infected patients under HAART, by (n-3) polyunsaturated fatty acids: a double-blind randomized prospective trial in 122 patients [abstract 39]. 12th Conference on Retroviruses and Opportunistic Infections. Boston, MA, February 22–25, 2005.



36. Wohl D, Tien HC, Busby M, et al. Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia. *Clin Infect Dis* 2005; 41:1498–1504.
37. Aberg JA, Zackin RA, Brobst SW, et al. A randomized trial comparing the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: ACTG 5087. *AIDS Res Hum Retroviruses* 2005; 21:757–767.
38. Viracept [package insert]. La Jolla, CA: Aguron Pharmaceuticals Inc, 2003.
39. Hsyu PH, Schultz-Smith MD, Lillibridge JH, Lewis RH, Kerr BM. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. *Antimicrob Agents Chemother* 2001; 45:3445–3450.
40. Kaletra [package insert]. North Chicago, IL: Abbott Laboratories, 2004.
41. Lexiva [package insert]. Research Triangle Park, NC: Glaxo Wellcome Inc.
42. Wire M, Baker K, Moore K. The pharmacokinetic (PK) interaction of GW433908 (908) with atorvastatin (ATO) and 908/ritonavir (RTV) with ATO (AVP 10013) [abstract no. A-1622]. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, September 14–17, 2003.
43. Gerber JG, Rosenkranz SL, Fichtenbaum CJ. The effect of efavirenz and nelfinavir on the pharmacokinetics of pravastatin [abstract no. 870]. 2nd International Conference on HIV Pathogenesis and Treatment, July 13–16, 2003.
44. Carr R, Andre A, Bertz R. Concomitant administration of ABT-378/ritonavir (ABT-378/r). Results in a clinically important pharmacokinetic (PK) interaction with atorvastatin but not pravastatin [abstract no. 1644]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, September 17–20, 2000.

.....  
**ADDRESS:** Marisa Tungsiripat, MD, Department of Infectious Diseases, S32, The Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, OH 44195; [tungsim@ccf.org](mailto:tungsim@ccf.org).